Key points are not available for this paper at this time.
Abstract The prognosis of patients with peripheral T‐cell lymphoma (PTCL) depends on bone marrow involvement (BMI). The bone marrow (BM) tumor microenvironment in PTCL remains unclear. We performed single‐cell RNA sequencing (scRNA‐seq) on 11 fresh BM samples from patients with BMI to reveal the associations of immune landscape and genetic variations with the prognosis of PTCL patients. Compared with PTCL not otherwise specified (NOS), angioimmunoblastic T‐cell lymphoma (AITL) had a higher number of T cells, lower number of lymphocytes, and greater inflammation. Immune heterogeneity in AITL is associated with prognosis. In particular, specific T‐cell receptor (TCR) T cells are enriched in patients with good response to anti‐CD30 therapy. We observed RhoA mutation‐associated neoantigens. Chidamide‐treated patients had a higher number of CD4+ regulatory cells and a better treatment response compared with other patients. In the nonresponder group, T‐cell enrichment progressed to secondary B‐cell enrichment and subsequently diffuse large B‐cell lymphoma. Moreover, AITL patients with lymphoma‐associated hemophagocytic syndrome had more T follicular helper (Tfh) cells with copy number variations in CHR5 . To our knowledge, this study is the first to reveal the single‐cell landscape of BM microenvironment heterogeneity in PTCL patients with BMI. scRNA‐seq can be used to investigate the immune heterogeneity and genetic variations in AITL associated with prognosis.
Liu et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: